Japan approves Amgen's migraine drug aimovig
In this article:
June 23 (Reuters) - Amgen Inc said on Wednesday that Japan had approved its drug aimovig, used for suppressing the onset of migraine attacks in adults.
The Japanese Ministry of Health, Labour and Welfare has granted marketing approval for the U.S.-based drugmaker's aimovig, making it the first approved treatment in the country to block the receptor that plays a critical role in migraine. (https://refini.tv/3gOJUrR)
(Reporting by Akriti Sharma in Bengaluru; Editing by Rashmi Aich)
